{"organizations": [], "uuid": "e6dfae2bbbc388d9d084dc069affd4acc61ec86c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/2", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/23/globe-newswire-obseva-sa-to-hold-investor-call-to-announce-topline-results-of-the-implant2-phase-3-clinical-trial-of-nolasiban-in-ivficsi.html", "country": "US", "domain_rank": 767, "title": "ObsEva SA to Hold Investor Call to announce Topline Results of the IMPLANT2 phase 3 Clinical Trial of Nolasiban in IVF/ICSI on Monday February 26, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.004, "site_type": "news", "published": "2018-02-24T00:00:00.000+02:00", "replies_count": 0, "uuid": "e6dfae2bbbc388d9d084dc069affd4acc61ec86c"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/23/globe-newswire-obseva-sa-to-hold-investor-call-to-announce-topline-results-of-the-implant2-phase-3-clinical-trial-of-nolasiban-in-ivficsi.html", "ord_in_thread": 0, "title": "ObsEva SA to Hold Investor Call to announce Topline Results of the IMPLANT2 phase 3 Clinical Trial of Nolasiban in IVF/ICSI on Monday February 26, 2018", "locations": [], "entities": {"persons": [], "locations": [{"name": "nolasiban", "sentiment": "none"}, {"name": "geneva", "sentiment": "none"}, {"name": "switzerland", "sentiment": "none"}, {"name": "boston", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "obseva sa", "sentiment": "neutral"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Geneva, Switzerland and Boston, MA - February 23, 2018 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that it will release the top line results from the IMPLANT2 clinical trial of its oxytocin receptor antagonist, Nolasiban, which is being developed for improving pregnancy rate following in vitro fertilization (IVF/ICSI) procedures, on the morning of Monday February 26, 2018. ObsEva management will host an investment community conference call at 8 a.m. Eastern Time, 2 p.m. Central European Time, on February 26, 2018 to discuss these results.\nInvestors may participate by dialing +1(844) 419-1772 for U.S. callers and +1(213) 660-0921 for international callers, and referring to conference ID 9784807. The webcast can be accessed under the \"Investors\" section of ObsEva's website www.obseva.com\nAbout ObsEva\nObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol \"OBSV\". For more information, please visit www.ObsEva.com .\n###\nMedia Contact:\nLiz Bryan\nSpectrum Science\nlbryan@spectrumscience.com\n202-955-6222 x2526\nCEO Office contact:\nShauna Dillon\nshauna.dillon@obseva.ch\n+41 22 552 1550\nInvestor Contact:\nMario Corso\nSenior Director, Investor Relations\nmario.corso@obseva.com\n781-366-5726\nAttachments:\nhttp://www.globenewswire.com/NewsRoom/AttachmentNg/875bf795-85d0-4113-b453-10a7f908f49c\nSource:ObsEva SA", "external_links": ["https://www.globenewswire.com/Tracker?data=WsXbKC5IfCto6tpMVVI4b_O-T7k9abiPk8uhTe-DoRo8ilqMNtMnMtBK59iLGIuOmxGyxMx5cnx0q3qk4L-kVUsNAwuv7aj9NzlK22rBxco=", "https://www.globenewswire.com/Tracker?data=_tWK7f8hGAKIG5UneFX4ECL9psJw6fVE8hHkeCwTMQJb1JuHBQpvAl1f304p5NdyZBnOGD9143hUnagGRlmUT3hB5jogqJOwAlK9y2JGGIjP38feS6nV9WxkiMIujprh", "https://www.globenewswire.com/Tracker?data=LSWjGL3eWdLP938enxKV6Rpo4OeuxLgXCWtsPLnXH-9CvHf_nDBvbmy8hBSAqf8mJ7953f-l4OxfYmR2nUU9Pw==", "https://www.globenewswire.com/Tracker?data=i72CcEBxWR8KBM5q4UauMdEKLYxMKyiCXipiMRtuLAC9doHqSChizEwTStvI1lYmRWtxVPbVdbZmNYzIY2ETliXikwFQ4CWNER2KCRvA-P4=", "http://www.globenewswire.com/NewsRoom/AttachmentNg/875bf795-85d0-4113-b453-10a7f908f49c", "https://www.globenewswire.com/NewsRoom/AttachmentNg/390cf3d9-f493-43bf-8d14-d2c6ebfc132b", "https://www.globenewswire.com/Tracker?data=5-6LKLUmPadHS9yLkh7EOP4kduiG1KZqNhTOIG_B436bj6cq3Vf4hr9FuSVe7C9nK_3-mfHnHeeTfEk50sCeuA==", "https://www.globenewswire.com/Tracker?data=INzW0ZCwzo2k7v1wOJjDv1PA2seobSb3CYUnHCKiqBBvaF0vVHBOffnWKnJoRZv2zsET24cy3KoRYssDibBewlFO-lh0GoMd5TCGRPvY4pWzOBK0R9WwVYQ4hwaqBXzxmRbG_tIx1unigdTaWsyoqtDxxkHsZ7wB_rcjWg1Fq-kv8frBC_vOUEGmUdfL2EjRB4_PjmmMNqlgHwQWcaksZy3YDI07JlXN9aVlf34dUgeapTToiYOXqshVN5Rd_ptDDvnru4uDjciTpXrMFpv1Jg=="], "published": "2018-02-24T00:00:00.000+02:00", "crawled": "2018-02-24T01:04:08.042+02:00", "highlightTitle": ""}